After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- US stock futures steady as oil jumps to two-week high ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
- Deutsche Bank Upgrades AST Spacemobile (ASTS) to Buy
- Stryker invests $400M in CMR Surgical with option to acquire
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'
March 19, 2025 10:08 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD)
The analyst comments "While recent reports (WSJ, Mar 18) suggest the Department of Health and Human Services may cut federal funding for HIV prevention, we believe... More
BTIG Reiterates Buy Rating on HealthEquity, Inc (HQY)
March 19, 2025 4:53 AM EDTBTIG analyst David Larsen reiterated a Buy rating and $130.00 price target on HealthEquity, Inc (NASDAQ: HQY).
The analyst comments "On Tuesday, 3/18/25 AMC, HQY reported F4Q:25 results. Total revenue of $311.8M +19% y/y was well ahead of BTIG / consensus estimates of $306.8M / $306M but adjusted EBITDA of $107.8M +9% y/y missed BTIG... More



